Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin for Subclinical Atherosclerosis in HIV/CMV Patients
NCT04101136Unknown
- Sponsor
- Dr. Cipto Mangunkusumo Hospital
- Start
- Sep 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in atherosclerosis comparing Atorvastatin 20 mg with Placebo (2 arms). Primary endpoint: Carotid intima medial tunica change at 48 weeks. Status: unknown.
02
Drugs
atorvastatin
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT04101136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04101136.